{
    "data": [
        {
            "title": "Cathay General Bancorp (CATY) Is Down 7.1% After Commercial Real Estate Credit Concerns Intensify",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In recent days, Cathay General Bancorp has come under pressure as investors reacted to rising credit risk concerns amid hotter-than-expected inflation data and growing worries over regional banks’ exposure to commercial real estate.</li> <li>What makes this episode especially important is that it coincides with Cathay General’s flat sales and declining earnings per share, sharpening questions about its profitability and growth profile.</li> <li>We’ll now examine how heightened credit risk concerns, particularly around commercial real estate, could reshape Cathay General Bancorp’s investment narrative.</li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Cathay General Bancorp Investment Narrative Recap</h2><p>To own Cathay General Bancorp, you need to believe its niche focus on Asian-American businesses and commercial lending will keep generating acceptable returns despite credit and profit headwinds. The recent selloff on rising credit risk and inflation worries goes straight to today’s key catalyst and risk: whether the bank can keep loan losses contained in commercial real estate while stabilizing earnings after flat sales and falling EPS.</p> <p>Against that backdrop, the recent dividend increase to US$0.38 per share is relevant because it signals the board’s current view of earnings strength and capital flexibility, even as credit concerns rise. For shareholders, it highlights the tension between a continuing income stream and growing questions about asset quality, particularly in commercial real estate and other potentially stressed loan categories.</p> <p>Yet beneath the reassuring dividend track record, there is a concentration risk in commercial real estate that investors should be aware of, especially if...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/banks/nasdaq-caty/cathay-general-bancorp/13p76qon-asian-american-demand-and-digital-banking-will-strengthen-performance-u3fm\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Cathay General Bancorp (it's free!)</a></p><p>Cathay General Bancorp's narrative projects $964.1 million revenue and $393.8 million earnings by 2028. This requires 11.0% yearly revenue growth and about a $99.1 million earnings increase from $294.7 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/banks/nasdaq-caty/cathay-general-bancorp/13p76qon-asian-american-demand-and-digital-banking-will-strengthen-performance-u3fm\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Cathay General Bancorp's forecasts yield a $54.20 fair value</a>, a 9% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-caty/cathay-general-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CATY 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/e07fdc51-7246-4f2c-b0ca-1887776f18c1/chart/quote-price\" width=\"746\"/></a><figcaption>CATY 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest ranked analysts were already cautious, assuming earnings of about US$381.0 million by 2028, and your view on commercial real estate risk could push you closer to that more pessimistic camp as this new credit scare unfolds.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/banks/nasdaq-caty/cathay-general-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\">Explore another fair value estimate on Cathay General Bancorp</a> - why the stock might be worth just $54.20!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Cathay General Bancorp research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-caty/cathay-general-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/banks/nasdaq-caty/cathay-general-bancorp\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Cathay General Bancorp research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cathay General Bancorp's overall financial health at a glance.</li></ul><h2>Curious About Other Options?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 21:01:57",
            "link": "https://simplywall.st/stocks/us/banks/nasdaq-caty/cathay-general-bancorp/news/cathay-general-bancorp-caty-is-down-71-after-commercial-real",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "The Bull Case For Bank of New York Mellon (BK) Could Change Following New Series M Preferred Offering",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>On February 26, 2026, Bank of New York Mellon Corporation priced and completed a US$500,000,000 underwritten public offering of 500,000 Series M Noncumulative Perpetual Preferred Stock depositary shares at US$1,000 each, featuring callable, non-cumulative, variable-rate terms.</li> <li>The planned use of proceeds for general corporate purposes, including potential redemptions of existing Series F and Series H preferred stock, signals a meaningful reshaping of BNY’s capital structure and future preferred dividend profile.</li> <li>Next, we’ll examine how issuing new Series M preferred shares and possible Series F and H redemptions may influence BNY’s investment narrative.</li> </ul><p>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Bank of New York Mellon Investment Narrative Recap</h2><p>To own Bank of New York Mellon Corporation, you need to believe its scale in custody, asset servicing, and wealth solutions can keep attracting institutional assets and fee income despite industry fee pressure and digital disruption. The new US$500,000,000 Series M preferred issuance looks like a technical capital-structure adjustment rather than a change to the core near term catalysts or the central risk of sustained fee and AUM pressure.</p> <p>The most relevant recent announcement is BNY’s Q4 2025 earnings, which showed continued profitability and supported ongoing common and preferred dividends. Set against that backdrop, the Series M preferred offering and potential Series F and H redemptions sit within a broader story of earnings quality, balance sheet resilience, and how much investors are willing to pay for relatively modest forecast growth.</p> <p>But investors should also be aware of the risk that fee growth stalls if passive investing and pricing pressure continue to...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nyse-bk/bank-of-new-york-mellon/vtzjcgoe-digital-transformation-and-partnerships-will-shape-financial-markets-of-tomorrow\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Bank of New York Mellon (it's free!)</a></p><p>Bank of New York Mellon Corporation’s narrative projects $21.3 billion revenue and $5.8 billion earnings by 2028. This requires 3.4% yearly revenue growth and a $1.0 billion earnings increase from $4.8 billion today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nyse-bk/bank-of-new-york-mellon/vtzjcgoe-digital-transformation-and-partnerships-will-shape-financial-markets-of-tomorrow\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Bank of New York Mellon's forecasts yield a $133.83 fair value</a>, a 12% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/diversified-financials/nyse-bk/bank-of-new-york-mellon\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"BK 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/6f385b2e-fe55-4795-935f-193ee51dce1e/chart/quote-price\" width=\"746\"/></a><figcaption>BK 1-Year Stock Price Chart</figcaption></figure> <p>Four fair value estimates from the Simply Wall St Community span about US$88 to US$134 per share, underscoring how far opinions can stretch. When you set that against the risk of structurally weaker fee growth if client outflows and passive trends persist, it becomes even more important to compare several viewpoints before deciding what you think BNY is really worth.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/diversified-financials/nyse-bk/bank-of-new-york-mellon\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 4 other fair value estimates on Bank of New York Mellon</a> - why the stock might be worth 26% less than the current price!</p><h2>Decide For Yourself</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Bank of New York Mellon research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nyse-bk/bank-of-new-york-mellon\" rel=\"noopener noreferrer\" target=\"_blank\">5 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/diversified-financials/nyse-bk/bank-of-new-york-mellon\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Bank of New York Mellon research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bank of New York Mellon's overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:</p><ul><li>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Bank of New York Mellon might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/diversified-financials/nyse-bk/bank-of-new-york-mellon/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 21:01:57",
            "link": "https://simplywall.st/stocks/us/diversified-financials/nyse-bk/bank-of-new-york-mellon/news/the-bull-case-for-bank-of-new-york-mellon-bk-could-change-fo-3",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Why Planet Fitness (PLNT) Is Down 9.4% After Tempered 2026 Guidance Despite Strong 2025 Results",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Planet Fitness reported higher Q4 and full-year 2025 revenue and earnings, alongside guidance for 2026 calling for approximately 9% revenue growth.</li> <li>At the same time, the company’s moderated growth outlook and ongoing legal investigations contrasted with continued international expansion, including new franchise-backed clubs in northern Mexico.</li> <li>We’ll now examine how Planet Fitness’s tempered 2026 guidance, despite solid 2025 results, reshapes the company’s longer-term investment narrative.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Planet Fitness Investment Narrative Recap</h2><p>To own Planet Fitness today, you have to believe its low cost, beginner friendly brand and franchise model can keep growing membership and club count, even if growth moderates. The key short term catalyst is how quickly member trends stabilize after “choppy” early 2026 activity, while the biggest risk is higher churn from click to cancel and legal scrutiny. The latest 9% revenue guidance and related stock drop reinforce, rather than change, those priorities.</p> <p>The most relevant update is Planet Fitness’s 2026 outlook for about 9% revenue growth, which came in below prior targets and coincided with a roughly 9% one day share price decline. This softer guidance matters because it directly challenges more optimistic expectations for accelerating revenue, and puts extra weight on near term membership retention, franchise economics and the payoff from recent club openings in 2025 and the planned capital spending increase in 2026.</p> <p>But while growth headlines grab attention, the bigger story investors should be aware of is the rising member churn risk and what it could mean for...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-plnt/planet-fitness/wb9jilna-global-club-expansion-and-youth-engagement-will-foster-future-success-fk2l\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Planet Fitness (it's free!)</a></p><p>Planet Fitness' narrative projects $1.6 billion revenue and $312.8 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-plnt/planet-fitness/wb9jilna-global-club-expansion-and-youth-engagement-will-foster-future-success-fk2l\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Planet Fitness' forecasts yield a $130.00 fair value</a>, a 58% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-plnt/planet-fitness\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PLNT 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a7366dce-ba7e-4208-826a-0b5698010796/chart/quote-price\" width=\"746\"/></a><figcaption>PLNT 1-Year Stock Price Chart</figcaption></figure> <p>Some of the most optimistic analysts were assuming revenue could reach about US$1.8 billion and earnings about US$334 million, but the new 9% growth outlook and higher churn risk show how quickly those narratives might need to be revisited and why your own view on Planet Fitness’s path from here really matters.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/consumer-services/nyse-plnt/planet-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Planet Fitness</a> - why the stock might be worth less than half the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Planet Fitness research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-plnt/planet-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/consumer-services/nyse-plnt/planet-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Planet Fitness research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Planet Fitness' overall financial health at a glance.</li></ul><h2>Looking For Alternative Opportunities?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 21:01:57",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-plnt/planet-fitness/news/why-planet-fitness-plnt-is-down-94-after-tempered-2026-guida",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "LandBridge (LB) Is Up 8.7% After Dividend Hike And New Buyback Plan - What's Changed",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In late February 2026, LandBridge Company LLC reported past fourth-quarter revenue of US$56.78 million and net income of US$8.06 million, alongside full-year 2025 revenue of US$199.09 million and net income of US$30.13 million, while also announcing a 20% dividend increase and a new US$50 million share repurchase program.</li> <li>This combination of strong earnings growth, a higher cash dividend, and a sizable buyback authorization underscores management’s confidence in LandBridge’s capital-light land model and its ability to generate and return cash to investors.</li> <li>Next, we’ll examine how the dividend increase and buyback authorization may influence LandBridge’s investment narrative and long-term appeal.</li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>LandBridge Investment Narrative Recap</h2><p>To own LandBridge, you need to believe its Permian-focused, capital-light land model can keep converting long-term energy and infrastructure demand into steady, fee-based cash generation. The latest results and capital return moves support the near-term earnings and cash flow story, but they do not fully remove the key near-term risk around timing delays on large projects and the longer term exposure to a single region and its regulatory and industrial cycles.</p> <p>The newly announced US$50 million share repurchase program through 2027 is especially relevant here, because it sits alongside a growing dividend and rising earnings, and together they draw more attention to how dependable LandBridge’s cash generation really is. If project timing, Permian-specific risks or customer concentration cause lumpier results than expected, that could challenge the perception that this level of capital returns is comfortably supported by the underlying business...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/real-estate-management-and-development/nyse-lb/landbridge/w8mc63ex-sunbelt-urbanization-and-permian-expansion-will-create-future-value-ezki\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on LandBridge (it's free!)</a></p><p>LandBridge's narrative projects $321.7 million revenue and $184.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/real-estate-management-and-development/nyse-lb/landbridge/w8mc63ex-sunbelt-urbanization-and-permian-expansion-will-create-future-value-ezki\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how LandBridge's forecasts yield a $73.00 fair value</a>, in line with its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-lb/landbridge\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"LB 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/1544c9f8-d4e7-434d-9e5a-3f4e5f55821d/chart/quote-price\" width=\"746\"/></a><figcaption>LB 1-Year Stock Price Chart</figcaption></figure> <p>Before this news, the most pessimistic analysts were assuming revenue of about US$296.1 million by 2028 and earnings of roughly US$186.3 million, yet still highlighted how long project lead times and potential delays in renewables or data center build out could leave earnings growth uneven. That more cautious view sits in clear tension with the strong 2025 results and fresh capital return plans, and it is a reminder that your own outlook might shift as new information comes through.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/real-estate-management-and-development/nyse-lb/landbridge\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 5 other fair value estimates on LandBridge</a> - why the stock might be worth as much as 21% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your LandBridge research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-lb/landbridge\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 1 important warning sign</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-lb/landbridge\" rel=\"noopener noreferrer\" target=\"_blank\">Our free LandBridge research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate LandBridge's overall financial health at a glance.</li></ul><h2>Seeking Other Investments?</h2><p>Our top stock finds are flying under the radar-for now. Get in early:</p><ul><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Outshine the giants: these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 early-stage AI stocks could fund your retirement</a>.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 21:01:57",
            "link": "https://simplywall.st/stocks/us/real-estate-management-and-development/nyse-lb/landbridge/news/landbridge-lb-is-up-87-after-dividend-hike-and-new-buyback-p",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Mirum Pharmaceuticals (MIRM) Valuation After Recent Share Price Volatility",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Mirum Pharmaceuticals stock snapshot after recent performance shifts</h2> <p>Mirum Pharmaceuticals (MIRM) has had mixed share-price moves recently, with a small 1 day gain, a 12% decline over the past week, a 10% drop over the past month, and a 32% gain across the past 3 months.</p> <p>Against that backdrop, investors are weighing Mirum’s current US$92.29 share price, its recent return profile over the past year and beyond, and how that lines up with the company’s rare disease portfolio and financial results.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Mirum Pharmaceuticals.</a></p> <p>Recent trading has been choppy, with short term share price pressure contrasted by stronger longer term total shareholder returns. This suggests that sentiment around Mirum’s rare disease portfolio and risk profile has been shifting rather than moving in a straight line.</p> <p>If Mirum’s moves have you thinking about where else growth stories might emerge in healthcare, it could be worth scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> as a starting point for ideas.</p> <p>With Mirum posting a 94% 1 year total return, rapid revenue and net income growth, and trading at US$92.29 versus an average analyst target of US$122.36, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?</p> <h2>Most Popular Narrative: 13.4% Undervalued</h2> <p>Against Mirum Pharmaceuticals' last close at $92.29, the most followed narrative points to a fair value of $106.60, anchored on detailed revenue and margin assumptions and a 7.17% discount rate.</p> <blockquote> <p><em>The analysts have a consensus price target of $78.273 for Mirum Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $89.0, and the most bearish reporting a price target of just $53.0.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/kbywinub-upcoming-clinical-milestones-will-drive-rare-disease-pipeline-expansion-into-2026\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what sits behind that fair value gap? The narrative leans on brisk revenue expansion, a swing to profitability, and a rich future earnings multiple. Curious how those pieces fit together and what assumptions really drive $106.60?</p> <p><strong>Result: Fair Value of $106.60 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/kbywinub-upcoming-clinical-milestones-will-drive-rare-disease-pipeline-expansion-into-2026\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, the current narrative still leans heavily on Livmarli and assumes smooth late stage trial execution, and any clinical setbacks or reimbursement pushback could quickly challenge that view.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Mirum Pharmaceuticals narrative.</a></p> <h2>Another view: pricing against sales multiples</h2> <p>The SWS DCF model points to a large gap between price and fair value, but the simple P/S check is more restrained. Mirum trades on a 10.7x P/S, above its 9.7x fair ratio, yet below both peer (12.7x) and wider US biotech averages (12.4x). Is that a margin of safety or a value trap forming?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGM:MIRM P/S Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/f966f0bc-3bcf-474b-a9d5-fe32e1bb6c62/chart/ps-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NasdaqGM:MIRM P/S Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>If this mix of optimism and caution feels familiar, now is a good time to look through the numbers yourself and decide where you stand. This includes <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards and 2 important warning signs</a>.</p> <h2>Ready for more investment ideas?</h2> <p>If Mirum has sharpened your thinking, do not stop there. Use the Simply Wall St screener to hunt for clear, data driven opportunities that suit your style.</p> <ul> <li>Target value potential by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that currently pair quality fundamentals with prices that may not fully reflect them.</li> <li>Prioritise staying power by checking the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a> that focus on companies with financial structures designed to handle pressure.</li> <li>Spot off the radar opportunities through the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that highlight quality businesses less crowded by attention.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 21:01:57",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mirm/mirum-pharmaceuticals/news/assessing-mirum-pharmaceuticals-mirm-valuation-after-recent-1",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Mitsubishi Gas Chemical Company (TSE:4182) Valuation After Dutch MXDA Project Cancellation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What the MXDA project cancellation means for Mitsubishi Gas Chemical Company (TSE:4182)</h2> <p>Mitsubishi Gas Chemical Company (TSE:4182) has formally decided to discontinue construction of its meta xylenediamine facility in the Netherlands, closing the door on a project that already led to asset impairment charges.</p> <p>The board weighed options such as restarting construction or partnering with another company. It concluded that the MXDA operation would not secure sufficient profit, so investors now face a clearer, though narrower, capital allocation path.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Mitsubishi Gas Chemical Company.</a></p> <p>The decision to shut down the Dutch MXDA project comes after a period of strong share price momentum, with Mitsubishi Gas Chemical Company’s 30 day share price return of 41.73% and 90 day return of 61.78%, alongside a 1 year total shareholder return of 97.88% that outpaces its shorter term moves.</p> <p>If this kind of portfolio reshaping has you looking beyond a single chemicals name, it could be a good moment to scan the market using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 top founder-led companies</a> and see what else stands out.</p> <p>With Mitsubishi Gas Chemical Company posting strong recent returns yet still trading at a small intrinsic discount, is the MXDA setback already reflected in the share price, or is the market quietly pricing in additional developments?</p> <h2>Preferred Price-to-Sales of 1.1x: Is it justified?</h2> <p>On our numbers, Mitsubishi Gas Chemical Company trades on a P/S of 1.1x, which screens as good value against peers even after the recent share price strength.</p> <p>P/S compares the company’s market value to its revenue and is often used for businesses where earnings are uneven or currently negative. This is the case here, with a reported loss of ¥16,252.0 on revenue of ¥739,862.0.</p> <p>At 1.1x, the market is paying a lower sales multiple than the peer average of 1.8x. This points to a discount on current revenue even though the company is unprofitable and forecast revenue growth of 4.1% a year is slower than the wider JP market forecast of 5.2%.</p> <p>Compared to the JP Chemicals industry average P/S of 0.8x, however, the shares sit at a premium. Our estimated fair P/S of 1x suggests some scope for the multiple to gravitate closer to that level over time if expectations cool or execution disappoints.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Mitsubishi Gas Chemical Company</a></p> <p><strong>Result: Price-to-Sales of 1.1x (ABOUT RIGHT)</strong></p> <p>However, you still have to weigh the recent loss of ¥16,252 and the board’s willingness to scrap projects that fall short against that small intrinsic discount.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Mitsubishi Gas Chemical Company narrative.</a></p> <h2>Another angle, our DCF model</h2> <p>While the 1.1x P/S ratio suggests Mitsubishi Gas Chemical Company is only slightly ahead of our fair ratio, our DCF model points to a different angle. At ¥4,364, the shares trade about 5.5% below our estimate of future cash flow value of ¥4,616.19. This raises the question of which signal should carry more weight for you.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"4182 Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/82082a30-5d87-4272-bd5d-f2b7291ac406/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>4182 Discounted Cash Flow as at Mar 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Mitsubishi Gas Chemical Company for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>Does this all leave you feeling cautious or curious about what comes next for Mitsubishi Gas Chemical Company? Take a moment to review the data yourself, weigh both sides of the story, and then check our breakdown of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> to see how those risks and rewards stack up.</p> <h2>Looking for more investment ideas?</h2> <p>If this update has sharpened your thinking, do not stop here. Use the Simply Wall St screener to line up your next set of candidates.</p> <ul> <li>Hunt for mispriced quality by checking out our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a> that may offer stronger fundamentals than their current tags suggest.</li> <li>Prioritise resilience with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/jp\" rel=\"noopener noreferrer\" target=\"_blank\">56 resilient stocks with low risk scores</a>, designed for investors who want steadier profiles front and center.</li> <li>Get ahead of the crowd by reviewing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/jp\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 58 high quality undiscovered gems</a> before others start paying attention.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:56:34",
            "link": "https://simplywall.st/stocks/jp/materials/tse-4182/mitsubishi-gas-chemical-shares/news/mitsubishi-gas-chemical-company-tse4182-valuation-after-dutc",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "How Array’s Tower Pivot And 2026 Revenue Guide At Array Digital Infrastructure (AD) Has Changed Its Investment Story",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Array Digital Infrastructure reported fourth-quarter 2025 revenue of US$60.33 million and net income of US$37.48 million, while issuing 2026 revenue guidance of US$200 million to US$215 million as it pivots toward tower and site rental income after selling regional wireless operations and most spectrum licenses.</li> <li>This shift is reshaping the company into a largely tower-focused business, with earnings now more closely tied to long-term lease agreements with major carriers rather than traditional retail wireless operations.</li> <li>We’ll now examine how this stronger tower-focused revenue base and 2026 guidance could influence Array Digital Infrastructure’s investment narrative.</li> </ul><p>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Array Digital Infrastructure Investment Narrative Recap</h2><p>To own Array Digital Infrastructure, you need to be comfortable with it becoming primarily a tower and site leasing company, where performance hinges on long-term contracts with major carriers and stable rental revenue. The latest quarter’s US$60.33 million in revenue and US$37.48 million in net income, alongside 2026 revenue guidance of US$200 million to US$215 million, supports that tower-focused story, but the key near term risk remains execution on this pivot and the durability of carrier demand rather than the recent handset or retail wireless headlines, which are not especially material here.</p> <p>Among recent developments, management’s 2026 revenue guidance of US$200 million to US$215 million stands out as the clearest reference point for the new tower-heavy model. It effectively replaces the prior wireless service metrics as the main yardstick many investors will watch against Array’s current valuation and income profile. How consistently the company delivers within or above that range, and how that ties to tower lease activity with carriers like T-Mobile, AT&amp;T, and Verizon, is likely to shape near term sentiment around the stock.</p> <p>Yet beneath this clearer tower story, investors should still be aware that...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/telecom/nyse-ad/array-digital-infrastructure/m7bdsy5m-t-mobile-deal-and-tower-agreements-will-drive-digital-infrastructure-transition\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Array Digital Infrastructure (it's free!)</a></p><p>Array Digital Infrastructure’s narrative projects $3.6 billion in revenue and $173.7 million in earnings by 2028. This requires a 0.8% yearly revenue decline and a $212.7 million earnings increase from -$39.0 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/telecom/nyse-ad/array-digital-infrastructure/m7bdsy5m-t-mobile-deal-and-tower-agreements-will-drive-digital-infrastructure-transition\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Array Digital Infrastructure's forecasts yield a $58.17 fair value</a>, a 19% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"AD 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3db14b9e-533a-4e69-ba4e-a10e8d4eae8e/chart/quote-price\" width=\"746\"/></a><figcaption>AD 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest ranked analysts were already cautious, penciling in revenue drifting lower and only modest margin improvement, so Array’s US$60.33 million quarter and US$200 million to US$215 million 2026 outlook may prompt them to revisit how much risk they see around tower reinvestment needs and earnings stability compared with the more constructive consensus view.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/telecom/nyse-ad/array-digital-infrastructure\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Array Digital Infrastructure</a> - why the stock might be worth as much as 22% more than the current price!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Array Digital Infrastructure research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Array Digital Infrastructure research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Array Digital Infrastructure's overall financial health at a glance.</li></ul><h2>No Opportunity In Array Digital Infrastructure?</h2><p>Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:</p><ul><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:56:34",
            "link": "https://simplywall.st/stocks/us/telecom/nyse-ad/array-digital-infrastructure/news/how-arrays-tower-pivot-and-2026-revenue-guide-at-array-digit",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Will Steady Dividends And A US$3.10 Billion Plan Shift MDU Resources Group's (MDU) Narrative",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>MDU Resources Group’s board recently declared a quarterly dividend of US$0.14 per share, unchanged from the prior quarter, payable on April 1, 2026 to shareholders of record on March 12, 2026, while continuing to target a long-term payout ratio of 60% to 70% of earnings.</li> <li>Alongside reaffirmed earnings guidance and a multi-year US$3.10 billion capital plan as a pure-play regulated utility and pipeline operator, the full exit of activist investor Corvex Management highlights an evolving shareholder base as MDU advances projects such as its 49% stake in Badger Wind.</li> <li>Now we’ll examine how MDU’s US$3.10 billion capital plan and pure-play regulated focus may influence its existing investment narrative.</li> </ul><p>Find <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>MDU Resources Group Investment Narrative Recap</h2><p>To own MDU Resources today, you need to believe in a focused, regulated utility and pipeline model where new capital projects can earn fair returns under supportive regulation. The key short term catalyst is execution on its US$3.10 billion capital plan, including projects like Badger Wind, while the biggest risk remains cost recovery and regulatory outcomes on that spending. The latest dividend affirmation and Corvex’s exit do not materially change that risk reward balance in the near term.</p> <p>The reaffirmed quarterly dividend of US$0.14 per share, with a 60% to 70% long term payout target, is the most relevant recent announcement here. It ties directly into the capital plan narrative, because sustaining that payout while funding US$3.10 billion of projects will likely depend on MDU’s ability to manage leverage, avoid equity dilution, and secure timely rate relief that supports earnings and cash flows from its regulated base.</p> <p>Yet beneath this steady dividend story, investors should be aware of the growing risk that rising capital needs and cost of capital could...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/utilities/nyse-mdu/mdu-resources-group/wewrhkcw-analyst-commentary-highlights-upgraded-targets-and-mixed-outlook-for-mdu-resources-group\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on MDU Resources Group (it's free!)</a></p><p>MDU Resources Group's narrative projects $2.0 billion revenue and $233.0 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/utilities/nyse-mdu/mdu-resources-group/wewrhkcw-analyst-commentary-highlights-upgraded-targets-and-mixed-outlook-for-mdu-resources-group\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how MDU Resources Group's forecasts yield a $20.80 fair value</a>, in line with its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/utilities/nyse-mdu/mdu-resources-group\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"MDU 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b72c7a56-cc45-4ee0-92bb-be1fd7c6626c/chart/quote-price\" width=\"746\"/></a><figcaption>MDU 1-Year Stock Price Chart</figcaption></figure> <p>While the consensus sees measured progress, the most optimistic analysts were already assuming revenue of about US$2.1 billion and earnings near US$224 million by 2028, so this latest capital plan and guidance could either reinforce or challenge those higher expectations depending on how you view the added regulatory and financing risks.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/utilities/nyse-mdu/mdu-resources-group\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on MDU Resources Group</a> - why the stock might be worth 10% less than the current price!</p><h2>Decide For Yourself</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your MDU Resources Group research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/utilities/nyse-mdu/mdu-resources-group\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 2 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/utilities/nyse-mdu/mdu-resources-group\" rel=\"noopener noreferrer\" target=\"_blank\">Our free MDU Resources Group research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate MDU Resources Group's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:56:33",
            "link": "https://simplywall.st/stocks/us/utilities/nyse-mdu/mdu-resources-group/news/will-steady-dividends-and-a-us310-billion-plan-shift-mdu-res",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Mazda Motor (TSE:7261) Valuation Check After Strong Recent Share Price Momentum",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Mazda Motor (TSE:7261) has drawn investor attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months, alongside reported revenue and net income figures.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Mazda Motor.</a></p> <p>Beyond the recent jump, Mazda Motor’s 30 day share price return of 22.28% and year to date share price return of 11.48% sit alongside a 1 year total shareholder return of 45.10%. This suggests that momentum has been building over both shorter and longer horizons.</p> <p>If Mazda’s recent move has you looking across the market, it could be a good moment to scan our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 top founder-led companies</a> as potential next ideas.</p> <p>With Mazda trading at ¥1,388.5 versus an average analyst target of ¥1,311.14 and an intrinsic value estimate suggesting an 8.07% premium, you need to ask whether there is still a buying opportunity here, or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Price-to-Earnings of 99.6x: Is it justified?</h2> <p>Mazda Motor is trading on a P/E of 99.6x, which sits alongside the recent share price of ¥1,388.5 and points to a rich earnings valuation relative to peers.</p> <p>The P/E ratio compares the current share price to earnings per share, so a higher P/E usually reflects the market paying more for each unit of current earnings. For Mazda, that high multiple sits against low net profit margins of 0.2% and a Return on Equity of 0.5%, which suggests the price is not being anchored by recent profitability.</p> <p>Relative signals back this up. Mazda is described as expensive versus the Asian Auto industry average P/E of 19.3x, and also high compared to the peer average P/E of 55.5x. Against an estimated fair P/E of 30.8x, the current 99.6x multiple is well above the level our models indicate the market could move towards if expectations cooled.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Mazda Motor</a></p> <p><strong>Result: Price-to-Earnings of 99.6x (OVERVALUED)</strong></p> <p>However, the high 99.6x P/E multiple, based on net income of ¥8,790 on revenue of ¥4,830,973 and a value score of 0, could limit upside if sentiment cools.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Mazda Motor narrative.</a></p> <h2>Another View: Cash Flows Tell a Similar Story</h2> <p>If you look at Mazda Motor through our DCF model instead of earnings multiples, the picture does not really soften. The shares at ¥1,388.5 sit above an estimated future cash flow value of ¥1,284.78, which points to an overvalued result here as well. So if both earnings and cash flows appear rich, what exactly is the market paying up for?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/automobiles/tse-7261/mazda-motor-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"7261 Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/25d36f4b-9eca-4726-9cf0-18907a8a0f3d/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>7261 Discounted Cash Flow as at Mar 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Mazda Motor for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>If this all feels one sided, it is worth remembering the market is weighing both concerns and reasons for optimism right now. Take a moment to review the full picture behind those risks and rewards with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 4 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>Do not park your research on a single company. Widen your watchlist now with a few focused stock ideas surfaced by the Simply Wall St screener.</p> <ul> <li>Target potential value by reviewing our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a> that pair strong fundamentals with prices that may not fully reflect them yet.</li> <li>Prioritise resilience with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/jp\" rel=\"noopener noreferrer\" target=\"_blank\">56 resilient stocks with low risk scores</a>, highlighting companies that score well on financial strength and risk factors.</li> <li>Hunt for under followed opportunities using our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/jp\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 58 high quality undiscovered gems</a>, where solid businesses may be getting less market attention than they deserve.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:56:33",
            "link": "https://simplywall.st/stocks/jp/automobiles/tse-7261/mazda-motor-shares/news/mazda-motor-tse7261-valuation-check-after-strong-recent-shar",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Nippn (TSE:2001) Valuation After ¥20 Billion Bond Issue Plans",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Nippn (TSE:2001) has announced plans to issue ¥20 billion in unsecured corporate bonds, carrying a 1.983% fixed coupon and maturing in 2031. This funding decision can influence views on its capital structure.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Nippn.</a></p> <p>At a share price of ¥2,867.0, Nippn has seen a 9.14% 1 month share price return and a 19.56% 3 month share price return, while its 1 year total shareholder return of 38.06% and 5 year total shareholder return of 97.55% point to momentum that has been building over time as investors reassess growth prospects and risk around moves like the new bond issue.</p> <p>If this bond news has you thinking about where capital might flow next, it could be a good moment to check out <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 top founder-led companies</a> as fresh ideas for your watchlist.</p> <p>With the new ¥20 billion bond issue on the table and the share price already reflecting solid recent returns, the real question for you is whether Nippn is still undervalued or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Price-to-Earnings of 11.5x: Is it justified?</h2> <p>Nippn’s shares closed at ¥2,867, and at that price the stock is described as trading on a P/E of 11.5x, with several checks pointing to it being on the cheaper side versus fair value estimates and peers.</p> <p>The P/E multiple compares the current share price with the company’s earnings per share. It gives a quick sense of how much investors are paying for each unit of profit. For a mature food business like Nippn, investors often look at this ratio to judge whether they are paying up for stability or getting a lower entry point relative to the sector.</p> <p>According to the data, Nippn is described as “good value” on several fronts. Its P/E of 11.5x is below an estimated “fair” P/E of 12.8x. It is also lower than the JP Food industry average of 17x and below a peer average of 14.6x, which suggests the market is pricing Nippn’s earnings more cautiously than many comparable companies.</p> <p>This kind of discount relative to both a fair ratio and sector peers can sometimes reflect concerns mentioned elsewhere, such as earnings being forecast to decline and recent pressure on profit margins, rather than any single short term event.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"fair_ratio_cta\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Explore the SWS fair ratio for Nippn</a></p> <p><strong>Result: Price-to-Earnings of 11.5x (UNDERVALUED)</strong></p> <p>However, you still need to weigh risks such as the 4.92% decline in annual net income and any strain from higher leverage after the ¥20b bond issue.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Nippn narrative.</a></p> <h2>Another View: Huge Gap On Our DCF Model</h2> <p>There is a very different picture when you look at Nippn through our DCF model. At a share price of ¥2,867, the stock is described as trading at a very large discount to an estimated future cash flow value of ¥27,048.18. This raises questions about how much risk or conservatism is built into that model.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Look into how the SWS DCF model arrives at its fair value.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"2001 Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/07145fc1-608b-44d6-b952-93229a566f2b/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>2001 Discounted Cash Flow as at Mar 2026</figcaption></figure><p> </p><p>Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (<a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares\" rel=\"noopener noreferrer\" target=\"_blank\">check out Nippn for example</a>). We show the entire calculation in full. You can track the result in your <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-watchlist\" rel=\"noopener noreferrer\" target=\"_blank\">watchlist</a> or <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/portfolio\" rel=\"noopener noreferrer\" target=\"_blank\">portfolio</a> and be alerted when this changes, or use our stock screener to discover <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a>. If you <a class=\"company-report-links\" data-vars-link-type=\"dcf_cta\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">save a screener</a> we even alert you when new companies match - so you never miss a potential opportunity.</p> <h2>Next Steps</h2> <p>If this mix of positives and concerns feels finely balanced, it makes sense to look at the full picture for yourself and act while the data is current. You can start with <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 4 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If you stop with just one stock, you risk missing other opportunities that fit your style, so use the screener now while these ideas are fresh.</p> <ul> <li>Spot potential bargains early by scanning our list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/jp\" rel=\"noopener noreferrer\" target=\"_blank\">20 high quality undervalued stocks</a> that pair appealing prices with solid fundamentals.</li> <li>Strengthen your income approach by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/jp\" rel=\"noopener noreferrer\" target=\"_blank\">12 dividend fortresses</a>, focused on companies offering yields that stand out.</li> <li>Sleep a bit easier by checking <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/jp\" rel=\"noopener noreferrer\" target=\"_blank\">56 resilient stocks with low risk scores</a>, centered on businesses with more resilient risk profiles.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Nippn might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 20:56:33",
            "link": "https://simplywall.st/stocks/jp/food-beverage-tobacco/tse-2001/nippn-shares/news/assessing-nippn-tse2001-valuation-after-20-billion-bond-issu",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Silverco Mining (TSXV:SICO) After Final 2025 Cusi Drill Results And Strong Recent Share Price Gains",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Silverco Mining (TSXV:SICO) has drawn fresh attention after reporting the final assay results from its 15,000 metre 2025 diamond drill program at the 100% owned Cusi Property in Chihuahua, Mexico.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Silverco Mining.</a></p> <p>The recent drilling update and February equity raise appear to be part of the backdrop to Silverco Mining’s strong momentum, with a 7 day share price return of 17.7%, a 30 day return of 25.6%, and a 90 day return of 140.4% from a latest share price of CA$13.82. Together, these figures suggest building optimism around the exploration story rather than short term trading alone.</p> <p>If this kind of move in a silver focused explorer has your attention, it could be worth widening your search with our screen of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_silver\" href=\"https://simplywall.st/discover/investing-ideas/473743/top-silver-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">7 top silver producer stocks</a> to see what else is on the radar.</p> <p>With zero revenue, a recent equity raise at CA$12.50 and a share price at CA$13.82 after very strong recent returns, you have to ask: is Silverco still mispriced, or is the market already banking on future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 93.1% Undervalued</h2> <p>According to the most followed narrative, Silverco Mining’s fair value of CA$199 sits far above the last close at CA$13.82, which frames the recent rally in a very different light.</p> <blockquote> <p><em>Silverco is a restart-stage, high-grade-ish silver district consolidator advancing the Cusi Mine Complex (underground mine + permitted 1,200 tpd mill) toward a restart decision, but the company explicitly says no production decision has been made yet, pending technical, financial, and permitting milestones.</em></p> </blockquote> <p><em>🗺️ Expected Timeline to Full Production 2026 (company framing): “resource update / restart plan / restart operations” (high-level). However, the official stance is that no production decision has been made yet until milestones are completed. Practical interpretation: until Silverco releases a restart study, financing, and a detailed schedule, any exact “full production” date would be guesswork.</em></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/0ox1qy9t-update-for-silverco-mining\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></p> <p>Curious how a zero revenue explorer gets to that CA$199 figure? The narrative leans on projected ounces, margins and a rich implied multiple that is far from conservative.</p> <p><strong>Result: Fair Value of CA$199 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_user_generated_narrative\" href=\"https://www.simplywall.st/narratives/0ox1qy9t-update-for-silverco-mining\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this narrative could quickly be tested if the restart decision is delayed further or if new technical work points to persistently high AISC.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Silverco Mining narrative.</a></p> <h2>Next Steps</h2> <p>If this all sounds optimistic or cautious to you, it is worth checking the facts yourself and forming your own take, especially given our findings of <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_analysis\" href=\"https://www.simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If Silverco has sparked your curiosity, do not stop here. Broaden your watchlist now with focused screens that surface opportunities you might otherwise miss.</p> <ul> <li>Scan for potential bargains by checking companies highlighted in our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a>, where pricing and fundamentals can tell a very different story to the headline narrative.</li> <li>Strengthen the quality of your watchlist by focusing on companies from the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/ca\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (10 results)</a>, so you are not ignoring balance sheet resilience.</li> <li>Spot under followed opportunities early by reviewing our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/ca\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 6 high quality undiscovered gems</a>, before they sit firmly on everyone else’s radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:50:56",
            "link": "https://simplywall.st/stocks/ca/materials/tsxv-sico/silverco-mining-shares/news/assessing-silverco-mining-tsxvsico-after-final-2025-cusi-dri",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is Vulcan Materials (VMC) Fully Priced After Strong Multi Year Share Price Gains",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>If you are wondering whether Vulcan Materials is a fair deal at around US$310 per share, it helps to step back and look at what the current price actually reflects.</li> <li>The stock last closed at US$310.00, with returns of 1.5% over 7 days, 3.1% over 30 days, 5.9% year to date, 26.3% over 1 year, 73.4% over 3 years and 92.3% over 5 years, which may shape how investors are thinking about its potential and its risks today.</li> <li>Recent coverage has focused on Vulcan Materials as a key supplier of construction aggregates in the US, with investors watching how its position in infrastructure and construction projects could influence sentiment. At the same time, broader market discussions around materials and construction stocks have given context to Vulcan's share price moves, as investors compare it to peers and sector trends.</li> <li>Despite that backdrop, Vulcan Materials currently has a valuation score of <a class=\"company-report-links\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">0 out of 6</a>. Next, we will look at how different valuation approaches, and a more holistic view at the end of the article, might help you judge whether the current price lines up with your own expectations.</li> </ul> <p>Vulcan Materials scores just 0/6 on our valuation checks. See what other red flags we found in the <a class=\"company-report-links\" data-vars-link-type=\"cta_low_value_score\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">full valuation breakdown</a>.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h3>Approach 1: Vulcan Materials Discounted Cash Flow (DCF) Analysis</h3> <p>A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today to get a single present value per share.</p> <p>For Vulcan Materials, the model used is a 2 Stage Free Cash Flow to Equity approach that starts from last twelve months free cash flow of about $1.07b. Analysts provide explicit projections through 2028, with free cash flow for that year modeled at $1.60b. Beyond that, Simply Wall St extrapolates out to 2035, generating a full 10 year cash flow path in dollar terms.</p> <p>When all those projected cash flows are discounted back, the DCF output points to an estimated intrinsic value of about $269.82 per share. Compared with the recent share price of US$310.00, this output indicates that Vulcan Materials is around 14.9% overvalued on this model.</p> <p>On this DCF view, the current market price is above the modelled cash flow value.</p> <p><strong>Result: OVERVALUED</strong></p> <p>Our Discounted Cash Flow (DCF) analysis suggests Vulcan Materials may be overvalued by 14.9%. <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">Discover 46 high quality undervalued stocks</a> or <a class=\"company-report-links\" data-vars-link-type=\"cta_dcf_overvalued\" href=\"https://simplywall.st/features/stock-screener\" rel=\"noopener noreferrer\" target=\"_blank\">create your own screener</a> to find better value opportunities.</p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"VMC Discounted Cash Flow as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b5c73fc4-1c78-42f4-b741-436f7057bd54/chart/dcf?date=2026-03-01\" width=\"746\"/></a><figcaption>VMC Discounted Cash Flow as at Mar 2026</figcaption></figure> <p><a class=\"company-report-links\" data-vars-link-type=\"dcf_explainer_cta\" href=\"https://www.simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Vulcan Materials.</a></p> <h3>Approach 2: Vulcan Materials Price vs Earnings</h3> <p>For a profitable company like Vulcan Materials, the P/E ratio is a useful way to see how much investors are currently paying for each dollar of earnings. In general, higher expected earnings growth or lower perceived risk can support a higher P/E, while lower growth or higher risk tends to align with a lower, more cautious multiple.</p> <p>Vulcan Materials is trading on a P/E of 37.44x. That compares with an average P/E of 15.56x for the wider Basic Materials industry and a peer group average of 27.79x, so the stock is priced above both of those reference points. Simply Wall St also calculates a proprietary “Fair Ratio” for Vulcan Materials of 24.44x. This is the P/E it might trade on given factors such as its earnings growth profile, profit margins, industry, market capitalization and risk characteristics.</p> <p>This Fair Ratio is more tailored than a simple peer or industry comparison because it adjusts for company specific drivers rather than assuming one size fits all. Lining up the current P/E of 37.44x against the Fair Ratio of 24.44x suggests Vulcan Materials is trading at a richer multiple than this model would indicate.</p> <p><strong>Result: OVERVALUED</strong></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-vmc/vulcan-materials/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:VMC P/E Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b5c73fc4-1c78-42f4-b741-436f7057bd54/chart/pe-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NYSE:VMC P/E Ratio as at Mar 2026</figcaption></figure> <p>P/E ratios tell one story, but what if the real opportunity lies elsewhere? <a class=\"company-report-links\" data-vars-link-type=\"cta_preferred_multiple_contextual\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">Start investing in legacies, not executives. Discover our 19 top founder-led companies</a>.</p> <h3>Upgrade Your Decision Making: Choose your Vulcan Materials Narrative</h3> <p>Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives, which are simply your own story about a company that you connect to a forecast for revenue, earnings and margins, then to a Fair Value that you can compare with the current price.</p> <p>On Simply Wall St, Narratives live in the Community page and are designed to be easy to use. You can plug in the assumptions you believe in, see the Fair Value that falls out of those numbers, and quickly judge whether that is above or below Vulcan Materials' current share price.</p> <p>Because Narratives update as new information comes in, such as earnings, guidance or news about highway spending and buybacks, your story and its Fair Value do not stay frozen. They move with the data so you can keep checking whether the gap between price and value still supports holding, trimming or adding.</p> <p>For Vulcan Materials, one investor might build a more optimistic Narrative closer to US$340 per share that leans on stronger infrastructure demand and margin expansion. Another might prefer a more cautious Narrative nearer US$190 to US$239.78 per share that leans on sustainability pressures, regulation and slower construction. Both can see in one place how their different stories link to different Fair Values and decisions.</p> <p>For Vulcan Materials, however, we will make it really easy for you with previews of two leading Vulcan Materials Narratives:</p> <p><a href=\"/us/materials/nyse-vmc/vulcan-materials/0leo7c01-highway-project-spending-and-pricing-trends-will-sustain-balanced-opportunity-ahead?utm_medium=finance_user&amp;utm_campaign=cta_bull_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>🐂 Vulcan Materials Bull Case</strong></a></p> <p>Fair value in this bullish Narrative: US$327.57 per share</p> <p>Gap to that fair value at the recent US$310.00 price: about 5.4% below the Narrative fair value</p> <p>Revenue growth assumption used: 5.34% a year</p> <ul> <li>Analysts in this camp expect infrastructure spending, Sunbelt demand and disciplined pricing to support revenue and earnings over several years.</li> <li>They factor in higher profit margins over time, supported by cost control, automation, acquisitions and a steady project pipeline.</li> <li>Their numbers line up with an analyst consensus price target around US$304.05 and a fair value estimate near US$327.57, with the view that the current price is broadly in line with those assumptions.</li> </ul> <p><a href=\"/us/materials/nyse-vmc/vulcan-materials/3wytubgl-shifting-urbanization-and-sustainability-will-erode-traditional-aggregates?utm_medium=finance_user&amp;utm_campaign=cta_bear_narrative_link&amp;utm_source=post\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><strong>🐻 Vulcan Materials Bear Case</strong></a></p> <p>Fair value in this bearish Narrative: US$264.31 per share</p> <p>Gap to that fair value at the recent US$310.00 price: about 14.8% above the Narrative fair value</p> <p>Revenue growth assumption used: 8.75% a year</p> <ul> <li>This group flags long term headwinds from sustainability trends, regulation, reserve quality and alternative building methods that could pressure traditional aggregate demand.</li> <li>They still model revenue and earnings growth, but think the P/E multiple implied by the current price asks too much of future execution and market conditions.</li> <li>Their updated fair value of about US$264.31 reflects those concerns, with the view that recent gains leave less room for error.</li> </ul> <p>Taken together, these Narratives frame a clear range for Vulcan Materials, from a more optimistic fair value near US$327.57 to a more cautious one around US$264.31. Your own view on volumes, margins and the P/E you are comfortable with will decide which story feels closer to reality.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_generic_community_narrative\" href=\"https://simplywall.st/features/community-narratives\" rel=\"noopener noreferrer\" target=\"_blank\">Curious how numbers become stories that shape markets? Explore Community Narratives</a></p> <p>Do you think there's more to the story for Vulcan Materials? <a class=\"company-report-links\" data-vars-link-type=\"cta_create_narrative_community\" href=\"https://simplywall.st/stock/NYSE/VMC\" rel=\"noopener noreferrer\" target=\"_blank\">Head over to our Community to see what others are saying!</a></p> <figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/materials/nyse-vmc/vulcan-materials\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NYSE:VMC 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/b5c73fc4-1c78-42f4-b741-436f7057bd54/chart/quote-price?date=2026-03-01\" width=\"746\"/></a><figcaption>NYSE:VMC 1-Year Stock Price Chart</figcaption></figure> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:50:56",
            "link": "https://simplywall.st/stocks/us/materials/nyse-vmc/vulcan-materials/news/is-vulcan-materials-vmc-fully-priced-after-strong-multi-year",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Xponential Fitness (XPOF) Valuation After Weak Earnings And Lower 2026 Revenue Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Xponential Fitness (XPOF) is back in focus after reporting fourth quarter and full year 2025 results, along with 2026 revenue guidance that points to a lower range than the prior year.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Xponential Fitness.</a></p> <p>The earnings release and lower 2026 revenue guidance have coincided with sharp share price weakness, with a 1 day share price return of 47.08% decline and a 1 year total shareholder return of 67.75% decline. This points to fading momentum and a reassessment of risk.</p> <p>If you are reassessing your exposure to consumer names after this update, it could be a good time to broaden your search with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With revenue at US$314.9 million in 2025, a net loss of US$38.7 million and 2026 guidance pointing lower, the steep share price pullback raises the key question: is XPOF now undervalued, or is the market correctly pricing in weaker growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 60.9% Undervalued</h2> <p>With Xponential Fitness closing at $4.26 against a widely followed fair value estimate of $10.90, the current setup reflects a wide valuation gap that hinges on long term assumptions about profitability and growth durability.</p> <blockquote> <p><em>The analysts have a consensus price target of $12.333 for Xponential Fitness based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.0, and the most bearish reporting a price target of just $9.0.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/k97fvnpr-international-expansion-will-capture-rising-wellness-demand-wotn\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what sits behind that fair value gap and wide analyst range? The narrative leans heavily on a sharp swing to profitability, higher margins and a future earnings multiple that assumes the franchise model keeps scaling efficiently. The exact mix of revenue growth, margin lift and discount rate doing the heavy lifting is all laid out in the full narrative.</p> <p><strong>Result: Fair Value of $10.90 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/k97fvnpr-international-expansion-will-capture-rising-wellness-demand-wotn\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, softer same-store sales and slower studio openings, combined with higher closures and leverage, could pressure royalties and challenge the bullish profitability path that analysts are using.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Xponential Fitness narrative.</a></p> <h2>Next Steps</h2> <p>If this mix of concern and optimism feels familiar, do not wait on the sidelines. Check the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a> to weigh the full picture for yourself.</p> <h2>Looking for more investment ideas?</h2> <p>If Xponential Fitness has you rethinking your watchlist, do not stop here. Use this moment to widen your opportunity set with a few focused stock ideas.</p> <ul> <li>Spot potential bargains first by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that pair quality with prices that may not fully reflect their fundamentals.</li> <li>Prioritise resilience with our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> so you can focus on companies that score well on stability instead of constantly worrying about shocks.</li> <li>Get ahead of the crowd by checking our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> before these names move onto everyone else's radar.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 20:50:56",
            "link": "https://simplywall.st/stocks/us/consumer-services/nyse-xpof/xponential-fitness/news/assessing-xponential-fitness-xpof-valuation-after-weak-earni",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "A Look At Collegium Pharmaceutical (COLL) Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Collegium Pharmaceutical (COLL) shares came under pressure after its Q4 and full year 2025 report, where earnings and revenue missed some analyst estimates, while management reaffirmed and slightly lifted 2026 guidance.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Collegium Pharmaceutical.</a></p> <p>The Q4 miss has come with a reset in expectations, with the 1 day share price return of a 5.77% decline at US$41.67 extending a 30 day share price return of a 9.26% decline, even though the 1 year total shareholder return of 43.44% and 5 year total shareholder return of 85.28% still point to investors who have stayed invested being rewarded over time.</p> <p>If this mix of short term volatility and longer term gains has you thinking about other opportunities in healthcare, it could be worth scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 healthcare AI stocks</a> as a starting list of ideas.</p> <p>With Collegium still trading below the average analyst price target and recent results combining record revenues with an earnings miss, you have to ask: Is this pullback a reset that leaves upside on the table, or is the market already baking in future growth?</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 22.4% Undervalued</h2> <p>Collegium Pharmaceutical's widely followed narrative pegs fair value at about $53.67 per share versus the last close of $41.67, framing the current pullback as potentially too harsh in the context of long term earnings power.</p> <blockquote> <p><em>The company's differentiated pain portfolio, notably with products featuring proprietary abuse deterrent and extended release technologies (e.g., Xtampza ER's DETERx platform), is supported by industry and regulatory trends that increasingly favor safer opioid options. This likely enhances market share, pricing power, and sustains net margins as regulatory emphasis on abuse deterrence grows.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what kind of profit margins and earnings path have to line up with that view? The most followed narrative leans on a very specific mix of modest revenue shifts, rising profitability and a future earnings multiple that is lower than many peers expect. The numbers behind that story are where the real tension sits.</p> <p><strong>Result: Fair Value of $53.67 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/tzlmd05y-specialty-pharmaceuticals-and-diversified-assets-will-drive-future-success-jtot\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, you also need to weigh risks, such as potential generic pressure on key pain brands and higher operating costs if expected Jornay PM traction does not fully show up.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Collegium Pharmaceutical narrative.</a></p> <h2>Another View: Multiples Paint A Pricier Picture</h2> <p>So far, the story leans on cash flows and long term earnings power suggesting Collegium looks undervalued. Yet on a simpler yardstick like P/E, the stock trades around 21x, above both peers at 18.1x and a fair ratio estimate of 18.2x. This suggests there may be less room for error if growth or margins disappoint.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"NasdaqGS:COLL P/E Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/9a27ea2f-6e12-4a81-a52d-45f720512ada/chart/pe-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>NasdaqGS:COLL P/E Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>Given the mixed signals in the story so far, it makes sense to move quickly and look through the numbers yourself, weighing up both sides of the argument. To see how the current share price lines up with the balance of risks and potential rewards, take a closer look at the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards and 2 important warning signs</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this earnings update has sharpened your focus, do not stop here; broaden your watchlist with a few targeted screens that surface different kinds of opportunities.</p> <ul> <li>Spot potential bargains early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that pair solid fundamentals with limited market attention.</li> <li>Build a foundation of strength by checking companies in the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/us\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (39 results)</a> that prioritise robust financial footing.</li> <li>Aim for a smoother ride by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_low_risk\" href=\"https://simplywall.st/discover/investing-ideas/473631/low-risk-leaders/us\" rel=\"noopener noreferrer\" target=\"_blank\">74 resilient stocks with low risk scores</a> that score well on our risk metrics while still offering upside potential.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 20:50:56",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-coll/collegium-pharmaceutical/news/a-look-at-collegium-pharmaceutical-coll-valuation-after-mixe",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Vaxcyte (PCVX) Is Up 5.5% After Unveiling VAX-31 Data, Phase 3 Plans And New Financing - Has The Bull Case Changed?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>In February 2026, Vaxcyte reported a full-year 2025 net loss of US$766.63 million and higher loss per share, while also raising roughly US$408.10 million through an at-the-market follow-on equity offering and filing additional shelf capacity linked to employee stock plans.</li> <li>Alongside these financing moves, the company highlighted unprecedented Phase 2 results for its VAX-31 pneumococcal vaccine, rapid progression into multiple Phase 3 trials, and completion of a large-scale manufacturing facility that together signal a major push toward potential commercialization of its vaccine portfolio.</li> <li>Next, we’ll examine how Vaxcyte’s unprecedented VAX-31 Phase 2 data and advancing Phase 3 program shape the company’s investment narrative.</li> </ul><p>The latest GPUs need a type of rare earth metal called Dysprosium and there are only <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>What Is Vaxcyte's Investment Narrative?</h2><p>For Vaxcyte, the core belief you need to have as a shareholder is that its pneumococcal and broader vaccine pipeline can translate extensive cash burn today into meaningful, defensible products tomorrow. The latest update sharpens that tradeoff. On one hand, the 2025 net loss widening to US$766.63 million reinforces that this is a pure clinical-stage story with no revenue and rising operating costs. On the other, raising about US$408.10 million via an at-the-market equity program, layering on new shelf capacity tied to employee stock plans, reporting unprecedented VAX-31 Phase 2 data, moving quickly into several Phase 3 trials and finishing a large-scale manufacturing facility all feed directly into the near-term catalysts: clinical readouts, regulatory milestones and potential partnering discussions. The key risk profile also shifts slightly, with financing risk reduced for now but dilution, trial execution and commercial build-out risks front and center. Overall, the February 2026 news is material because it both extends the funding runway and accelerates the company toward its most binary events.</p> However, investors should not overlook how rising losses and ongoing dilution could affect future outcomes.\n\nVaxcyte's shares have been on the rise but are still potentially undervalued by 33%. <a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">Find out what it's worth</a>.<h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"PCVX 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/a5c22673-aeb2-4b4c-9e84-eb62a6baad5a/chart/quote-price\" width=\"746\"/></a><figcaption>PCVX 1-Year Stock Price Chart</figcaption></figure> Three Simply Wall St Community fair values, from US$10.90 to US$109.00, show just how far apart expectations sit. Set against escalating losses and heavier reliance on trial success, it underlines why you should weigh multiple viewpoints before deciding how Vaxcyte fits in your portfolio.<p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on Vaxcyte</a> - why the stock might be worth as much as 77% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Vaxcyte research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Vaxcyte research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Vaxcyte's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Opportunities like this don't last. These are today's most promising picks. Check them out now:</p><ul><li>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</li><li>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">30 elite penny stocks</a> that balance risk and reward.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:50:56",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-pcvx/vaxcyte/news/vaxcyte-pcvx-is-up-55-after-unveiling-vax-31-data-phase-3-pl",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Perdoceo Education’s (PRDO) Valuation After Earnings Growth Guidance And Dividend Affirmation",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><p>Perdoceo Education (PRDO) drew fresh attention after reporting fourth quarter and full year 2025 earnings, issuing new 2026 guidance, and affirming its quarterly dividend, giving investors several data points to reassess the stock.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-prdo/perdoceo-education\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Perdoceo Education.</a></p> <p>The recent earnings, 2026 guidance and dividend affirmation come after a period of steady share price strength, with a 90 day share price return of 19.83% and a 1 year total shareholder return of 32.10% supporting a much larger 3 year total shareholder return of about 2.6x.</p> <p>If this update has you looking beyond a single education stock, it could be a good time to broaden your watchlist with <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_founder_led\" href=\"https://simplywall.st/discover/investing-ideas/473625/top-founder-led-companies/us\" rel=\"noopener noreferrer\" target=\"_blank\">19 top founder-led companies</a>.</p> <p>With strong recent returns, earnings growth and a dividend on the table, the key question now is whether Perdoceo’s current price still offers value or if the market is already pricing in future growth.</p> <div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Most Popular Narrative: 20.6% Undervalued</h2> <p>Perdoceo Education's most followed narrative places fair value at $42, above the last close of $33.35. This frames the stock as materially discounted and puts the focus squarely on the earnings and enrollment story behind that gap.</p> <blockquote> <p><em>Continued expansion of high-demand, industry-aligned programs (notably in nursing, speech language therapy, and healthcare doctorate programs) and introduction of flexible learning modalities (online, in-person, hybrid) positions the company to capture premium tuition and adapt to evolving workforce upskilling needs, supporting both revenue growth and higher net margins.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/yv132eii-enrollment-trends-and-student-support-technologies-will-shape-future-education-jujp\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Want to see what powers that higher fair value, beyond recent earnings? The narrative leans heavily on specific revenue growth, margin assumptions and how future P/E levels compare with the broader Consumer Services group, but the exact thresholds might surprise you.</p> <p><strong>Result: Fair Value of $42 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/yv132eii-enrollment-trends-and-student-support-technologies-will-shape-future-education-jujp\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, this depends on enrollment and margin trends holding up, and tighter regulation or rising student acquisition costs could quickly challenge that upbeat valuation story.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-prdo/perdoceo-education\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Perdoceo Education narrative.</a></p> <h2>Next Steps</h2> <p>If the mixed signals in this story leave you on the fence, now is a good moment to check the numbers yourself and decide where you stand, including our view on <a class=\"company-report-links\" data-vars-link-type=\"cta_rewards_analysis\" href=\"https://www.simplywall.st/stocks/us/consumer-services/nasdaq-prdo/perdoceo-education\" rel=\"noopener noreferrer\" target=\"_blank\">4 key rewards</a>.</p> <h2>Looking for more investment ideas?</h2> <p>If this Perdoceo update sharpened your thinking, do not stop here, use the Simply Wall St screener to uncover other ideas that could reshape your portfolio.</p> <ul> <li>Target potential mispricings by scanning a data backed list of <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 high quality undervalued stocks</a> that might not be getting full credit from the market yet.</li> <li>Strengthen your income stream by reviewing <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> that aim to combine higher yields with balance sheet support.</li> <li>Get ahead of the crowd by checking a <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undiscovered_gems\" href=\"https://simplywall.st/discover/investing-ideas/473622/high-quality-undiscovered-gems/us\" rel=\"noopener noreferrer\" target=\"_blank\">screener containing 24 high quality undiscovered gems</a> that many investors may not be watching closely yet.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/portfolio\" target=\"_blank\">Try a Demo Portfolio for Free</a></div></div>",
            "pub_date": "2026-03-01 20:42:04",
            "link": "https://simplywall.st/stocks/us/consumer-services/nasdaq-prdo/perdoceo-education/news/assessing-perdoceo-educations-prdo-valuation-after-earnings",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Claritev (CTEV) Is Down 42.1% After Launching $75 Million Buyback Amid Ongoing Losses - What's Changed",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Claritev Corporation recently reported past fourth-quarter 2025 sales of US$246.55 million and a net loss of US$80.57 million, alongside full-year 2025 sales of US$965.41 million and a net loss of US$284.28 million, and announced a new share repurchase program of up to US$75 million running through 2030.</li> <li>While the company remains loss-making, the year-on-year reduction in losses and the commitment to buying back shares suggest management is focused on improving financial discipline and capital allocation.</li> <li>Next, we’ll examine how Claritev’s reduced losses and new US$75 million share repurchase program may influence its existing investment narrative.</li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">31 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Claritev Investment Narrative Recap</h2><p>To own Claritev, you need to believe its healthcare analytics platform can convert a concentrated client base and ongoing digital investments into a path toward smaller losses and eventually sustainable margins. The latest results show narrower losses and modest revenue growth, but the key near term catalyst remains whether Claritev can keep reducing losses while stabilizing its balance sheet. The biggest risk is still its dependence on a few large payor and TPA relationships, and this update does not materially change that.</p> <p>The new US$75 million share repurchase program, capped at US$20 million per year through 2030, is the most relevant announcement here. It intersects directly with the near term focus on cost control and cash generation, since buybacks will draw on cash on hand and operating cash flows. For investors, the real test is whether Claritev can support this program while funding ongoing AI, cloud, and international initiatives that underpin its longer term growth catalysts.</p> <p>Yet even with shrinking losses and a buyback in place, investors still need to weigh the concentration risk in Claritev’s largest client contracts and...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/healthcare/nyse-ctev/claritev/tkit8a2w-analysts-boost-claritev-valuation-amid-growth-optimism-and-strategic-developments\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Claritev (it's free!)</a></p><p>Claritev's narrative projects $1.0 billion revenue and $90.0 million earnings by 2028. This requires 3.1% yearly revenue growth and a $753.4 million earnings increase from $-663.4 million today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/healthcare/nyse-ctev/claritev/tkit8a2w-analysts-boost-claritev-valuation-amid-growth-optimism-and-strategic-developments\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Claritev's forecasts yield a $57.25 fair value</a>, a 325% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/healthcare/nyse-ctev/claritev\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"CTEV 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/e4284142-c859-4628-ae85-f9d61db99e60/chart/quote-price\" width=\"746\"/></a><figcaption>CTEV 1-Year Stock Price Chart</figcaption></figure> <p>By contrast, the most cautious analysts were already assuming only about 3.4 percent annual revenue growth to roughly US$1.0 billion and no near term profitability, so this earnings and buyback update could either reinforce their concerns about margin pressure from rising costs or gradually challenge that view, depending on how you interpret Claritev’s progress and which risks you think matter most.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/healthcare/nyse-ctev/claritev\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 2 other fair value estimates on Claritev</a> - why the stock might be a potential multi-bagger!</p><h2>The Verdict Is Yours</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Claritev research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/healthcare/nyse-ctev/claritev\" rel=\"noopener noreferrer\" target=\"_blank\">1 key reward and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/healthcare/nyse-ctev/claritev\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Claritev research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Claritev's overall financial health at a glance.</li></ul><h2>Searching For A Fresh Perspective?</h2><p>Every day counts. These free picks are already gaining attention. See them before the crowd does:</p><ul><li>Find <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">46 companies with promising cash flow potential yet trading below their fair value</a>.</li><li>The latest GPUs need a type of rare earth metal called Neodymium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>The future of work is here. Discover the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473746/robotics-andamp-automation-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">30 top robotics and automation stocks</a> leading the charge in AI-driven automation and industrial transformation.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 20:42:03",
            "link": "https://simplywall.st/stocks/us/healthcare/nyse-ctev/claritev/news/claritev-ctev-is-down-421-after-launching-75-million-buyback",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Assessing Chartwell Retirement Residences (TSX:CSH.UN) Valuation After Its Multi‑Year Share Price Momentum",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Why Chartwell Retirement Residences is on investors’ radar</h2> <p>Chartwell Retirement Residences (TSX:CSH.UN) has drawn investor attention after a period of steady share price gains, with the unit price recently closing at CA$22.22 and showing solid returns across multiple time frames.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_company_latest_analysis\" href=\"https://www.simplywall.st/stocks/ca/healthcare/tsx-csh.un/chartwell-retirement-residences-shares\" rel=\"noopener noreferrer\" target=\"_blank\">See our latest analysis for Chartwell Retirement Residences.</a></p> <p>Those recent moves come on top of a 9.9% 1 month share price return and an 11.7% year to date share price return. The 1 year total shareholder return of 36.6% and very large 3 and 5 year total shareholder returns suggest momentum has been building over several years rather than just in the latest rally.</p> <p>If Chartwell’s run has you thinking more broadly about where capital could work hardest next, it may be worth scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_healthcare_ai\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/ca\" rel=\"noopener noreferrer\" target=\"_blank\">4 healthcare AI stocks</a> for fresh ideas across the sector.</p> <p>With Chartwell generating revenue of CA$1.11b and net income of CA$29.41m, and trading only slightly below a CA$23.70 analyst price target, it is worth asking whether there is still a buying opportunity here or whether the market is already pricing in future growth.</p> <h2>Most Popular Narrative: 3.6% Undervalued</h2> <p>On the most followed narrative, Chartwell’s fair value comes out at CA$23.05, a touch above the CA$22.22 last close. This puts the focus on what assumptions are doing the heavy lifting.</p> <blockquote> <p><em>Chartwell's financial results and guidance point to a sustained increase in demand for senior housing, driven by a rapidly growing seniors population and persistent supply constraints, supporting rising occupancy and driving long term revenue and NOI growth. The company is executing on a strategy of acquiring and developing newer, larger, and more operationally efficient properties expected to produce higher occupancy rates, greater per suite NOI, and enhanced margins as lease ups mature.</em></p> </blockquote> <p><em><a class=\"company-report-links\" data-vars-link-type=\"cta_narrative_prompt_after_quote\" href=\"https://www.simplywall.st/narratives/q5a1jmtt-senior-housing-demand-will-build-sustained-market-leadership-5fl7\" rel=\"noopener noreferrer\" target=\"_blank\">Read the complete narrative.</a></em></p> <p>Curious what sits behind that CA$23.05 figure? The narrative leans on robust top line expansion, firmer margins, and a rich future earnings multiple that is described as anything but conservative.</p> <p><strong>Result: Fair Value of CA$23.05 (UNDERVALUED)</strong></p> <p><a class=\"company-report-links\" data-vars-link-type=\"cta_ai_narrative\" href=\"https://www.simplywall.st/narratives/q5a1jmtt-senior-housing-demand-will-build-sustained-market-leadership-5fl7\" rel=\"noopener noreferrer\" target=\"_blank\">Have a read of the narrative in full and understand what's behind the forecasts.</a></p> <p>However, the picture could change if elevated leverage and refinancing costs squeeze margins, or if higher labour expenses erode the modest profit improvements that analysts are banking on.</p> <p><a class=\"company-report-links\" data-vars-link-type=\"risks_narrative_cta\" href=\"https://www.simplywall.st/stocks/ca/healthcare/tsx-csh.un/chartwell-retirement-residences-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Find out about the key risks to this Chartwell Retirement Residences narrative.</a></p> <h2>Another angle: rich sales multiple vs fair ratio</h2> <p>The AI fair value story leans toward modest undervaluation, but the sales multiple tells a different tale. Chartwell trades on a P/S of 6.4x, far above the North American Healthcare industry at 1.2x and peers at 1.3x, and well ahead of its own fair ratio of 3.5x.</p> <p>That gap suggests the market is already paying a premium for future growth. This leaves less room for error if margins, interest costs or occupancy do not line up with expectations. How comfortable are you paying almost double the fair ratio for that growth story?</p> <p><a class=\"company-report-links\" data-vars-link-type=\"alternate_preferred_multiple_cta\" href=\"https://www.simplywall.st/stocks/ca/healthcare/tsx-csh.un/chartwell-retirement-residences-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\">See what the numbers say about this price — find out in our valuation breakdown.</a></p> <p></p><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://www.simplywall.st//stocks/ca/healthcare/tsx-csh.un/chartwell-retirement-residences-shares/valuation\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSX:CSH.UN P/S Ratio as at Mar 2026\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/98b989bf-47b7-42e2-9ef4-25adfac3feb0/chart/ps-multiple-vs-industry?date=2026-03-01\" width=\"746\"/></a><figcaption>TSX:CSH.UN P/S Ratio as at Mar 2026</figcaption></figure><p> </p><h2>Next Steps</h2> <p>Mixed signals or a clear story: this is a good moment to look under the hood yourself and move quickly rather than follow the crowd. To understand how the positives stack up against the concerns, take a look at the <a class=\"company-report-links\" data-vars-link-type=\"cta_risks_rewards_analysis\" href=\"https://www.simplywall.st/stocks/ca/healthcare/tsx-csh.un/chartwell-retirement-residences-shares\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> and weigh the trade off for your own portfolio.</p> <h2>Looking for more investment ideas?</h2> <p>If Chartwell has sharpened your focus, do not stop here. Your next strong idea could be waiting just outside your current watchlist.</p> <ul> <li>Spot potential value opportunities early by scanning our <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_undervalued\" href=\"https://simplywall.st/discover/investing-ideas/473076/high-quality-undervalued-stocks/ca\" rel=\"noopener noreferrer\" target=\"_blank\">8 high quality undervalued stocks</a> and see which businesses currently look priced below what their fundamentals suggest.</li> <li>Strengthen your portfolio’s foundations with companies from the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_solid_balance_sheet\" href=\"https://simplywall.st/discover/investing-ideas/10146/solid-balance-sheet-and-fundamentals/ca\" rel=\"noopener noreferrer\" target=\"_blank\">solid balance sheet and fundamentals stocks screener (10 results)</a> that combine financial resilience with underlying business quality.</li> <li>Boost your income watchlist by reviewing the <a class=\"company-report-links\" data-vars-link-type=\"cta_screener_dividend\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/ca\" rel=\"noopener noreferrer\" target=\"_blank\">5 dividend fortresses</a> and find yields that could complement holdings like Chartwell.</li> </ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\"><strong>New: </strong>AI Stock Screener &amp; Alerts</h3><p>Our new AI Stock Screener scans the market every day to uncover opportunities.</p><p>• Dividend Powerhouses (3%+ Yield)<br/>• Undervalued Small Caps with Insider Buying<br/>• High growth Tech and AI Companies<br/><br/>Or build your own from over 50 metrics.</p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"https://simplywall.st/features/stock-screener\" target=\"_blank\">Explore Now for Free</a></div></div>",
            "pub_date": "2026-03-01 20:42:03",
            "link": "https://simplywall.st/stocks/ca/healthcare/tsx-csh.un/chartwell-retirement-residences-shares/news/assessing-chartwell-retirement-residences-tsxcshun-valuation",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Nidec (TSE:6594) Is Up 7.0% After Earnings Beat And Founder Exit During Accounting Probe",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>Nidec Corporation recently reported a Q3 earnings beat with upgraded guidance and a sharper focus on stabilizing margins in its industrial and automotive businesses, while founder Shigenobu Nagamori resigned as Chairman Emeritus amid an ongoing third-party accounting probe.</li> <li>Together, improved operational signals and a governance reset during the probe mark an important moment for assessing Nidec’s earnings quality and corporate oversight.</li> <li>Next, we’ll explore how Nagamori’s resignation during the accounting probe reshapes Nidec’s existing investment narrative and risk‑reward profile.</li> </ul><p>Invest in the nuclear renaissance through our list of <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/473644/nuclear-renaissance/global\" rel=\"noopener noreferrer\" target=\"_blank\">84 elite nuclear energy infrastructure plays</a> powering the global AI revolution.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>Nidec Investment Narrative Recap</h2><p>To own Nidec, you need to believe its restructuring, cost cuts, and exposure to electrification and data centers can translate into stronger, cleaner earnings despite cyclical end markets. Right now, the most important near term catalyst is clarity from the accounting probe, because it directly affects confidence in Nidec’s reported margins and cash flows. The biggest risk is that any control weaknesses or legal findings prove deeper than currently known and weigh on profitability.</p> <p>Against that backdrop, the latest Q3 earnings beat and upgraded guidance matter because they show progress on margin stabilization in industrial motors and automotive, which sits at the core of the restructuring story. Stronger earnings and cash flow provide more flexibility for Nidec to keep investing in motors for data centers and EVs while absorbing any near term costs related to governance reforms and potential compliance fixes.</p> <p>Yet investors should also be aware that the ongoing trade compliance investigations could still...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/capital-goods/tse-6594/nidec-shares/ahdigll5-6594-new-arkansas-expansion-will-drive-positive-momentum-into-2027\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on Nidec (it's free!)</a></p><p>Nidec's narrative projects ¥2,893.2 billion revenue and ¥247.5 billion earnings by 2028. This requires 3.7% yearly revenue growth and about a ¥90.1 billion earnings increase from ¥157.4 billion today.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/capital-goods/tse-6594/nidec-shares/ahdigll5-6594-new-arkansas-expansion-will-drive-positive-momentum-into-2027\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how Nidec's forecasts yield a ¥2995 fair value</a>, a 22% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/jp/capital-goods/tse-6594/nidec-shares\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"TSE:6594 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/040c61a6-455f-4a12-9141-627a6be40a0b/chart/quote-price\" width=\"746\"/></a><figcaption>TSE:6594 1-Year Stock Price Chart</figcaption></figure> <p>Some analysts were far more optimistic, assuming revenue could reach about ¥3,030.4 billion and earnings about ¥285.8 billion by 2028, but the latest governance shock may prompt you to rethink how realistic that path looks and whether the probe and chairman’s exit change the balance between upside from restructuring and the risk that compliance issues keep margins under pressure.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/jp/capital-goods/tse-6594/nidec-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 4 other fair value estimates on Nidec</a> - why the stock might be worth as much as 67% more than the current price!</p><h2>Form Your Own Verdict</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your Nidec research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/jp/capital-goods/tse-6594/nidec-shares\" rel=\"noopener noreferrer\" target=\"_blank\">3 key rewards</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/jp/capital-goods/tse-6594/nidec-shares\" rel=\"noopener noreferrer\" target=\"_blank\">Our free Nidec research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nidec's overall financial health at a glance.</li></ul><h2>Contemplating Other Strategies?</h2><p>Our daily scans reveal stocks with breakout potential. Don't miss this chance:</p><ul><li>Rare earth metals are the new gold rush. Find out which <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 stocks are leading the charge</a>.</li><li>The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434414/ai-penny-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">22 smaller AI-focused companies with strong growth potential</a> through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.</li><li>Capitalize on the AI infrastructure supercycle with our selection of the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473744/ai-infrastructure-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">34 best 'picks and shovels' of the AI gold rush</a> converting record-breaking demand into massive cash flow.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if Nidec might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/jp/capital-goods/tse-6594/nidec-shares/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 20:42:03",
            "link": "https://simplywall.st/stocks/jp/capital-goods/tse-6594/nidec-shares/news/nidec-tse6594-is-up-70-after-earnings-beat-and-founder-exit",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        },
        {
            "title": "Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU?",
            "description": "<div class=\"sc-d08486b0-3 byoTNg\" data-cy-id=\"article-content\"><ul> <li>EyePoint, Inc. recently appointed Michael Campbell as Chief Commercial Officer, giving him responsibility for commercial strategy and launch preparation for DURAVYU, its Phase 3 retinal disease candidate. </li> <li>The hire brings in a leader who helped shape the commercial playbooks behind Lucentis, Xiidra, Beovu and Tyrvaya, directly relevant to DURAVYU’s target markets. </li> <li>We’ll now examine how adding a veteran ophthalmology launch executive to oversee DURAVYU’s commercialization may influence EyePoint’s broader investment narrative. </li> </ul><p>Uncover the next big thing with <a class=\"company-report-links\" data-vars-link-type=\"intro\" href=\"https://simplywall.st/discover/investing-ideas/472945/elite-penny-stocks/us\" rel=\"noopener noreferrer\" target=\"_blank\">31 elite penny stocks</a> that balance risk and reward.</p><div class=\"relative grid grid-rows-[25px_auto] place-items-center bg-surface @container/article-body-ad [[data-brand='v2']_&amp;]:bg-surface-1\" data-cy-id=\"article-body-ad\"><div class=\"text-tiny text-softer\">Advertisement</div><div class=\"relative h-[250px] min-h-[250px] w-[300px] min-w-[300px] @[380px]/article-body-ad:h-[280px] @[380px]/article-body-ad:min-h-[280px] @[380px]/article-body-ad:w-[336px] @[380px]/article-body-ad:min-w-[336px]\"><div data-fuse=\"news_incontent_1\" id=\"news_incontent_1\"></div></div></div><h2>EyePoint Investment Narrative Recap</h2><p>To own EyePoint today, you really have to believe DURAVYU can graduate from a Phase 3 program into a meaningful commercial franchise before cash burn becomes overwhelming. The Michael Campbell hire directly targets the key short term catalyst, a potential DURAVYU launch, but it does not change the fact that any delay or disappointment in the pivotal trials remains the central risk for a company with minimal current revenue.</p> <p>Among recent announcements, the Phase 3 DURAVYU update following the second DSMC review in November 2025 is most relevant here, because it kept the pivotal program on track toward potential commercialization. Campbell’s arrival now sits on top of that clinical backdrop, linking trial progress with an increasingly built out launch and manufacturing footprint, which together frame both the upside catalyst of a successful entry into wet AMD and DME and the execution risk if uptake proves slower than expected.</p> <p>Yet against that excitement, investors should be aware that...</p> <p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/nwrya9z6-phase-iii-trials-in-wet-amd-will-expand-market-reach-ncqs\" rel=\"noopener noreferrer\" target=\"_blank\">Read the full narrative on EyePoint (it's free!)</a></p><p>EyePoint's narrative projects $146.7 million revenue and $34.1 million earnings by 2028.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/nwrya9z6-phase-iii-trials-in-wet-amd-will-expand-market-reach-ncqs\" rel=\"noopener noreferrer\" target=\"_blank\">Uncover how EyePoint's forecasts yield a $36.08 fair value</a>, a 105% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><a class=\"company-report-links\" data-vars-link-type=\"infographic\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\"><img alt=\"EYPT 1-Year Stock Price Chart\" class=\"sc-3204b94-0 iJdSPa\" height=\"476\" loading=\"lazy\" src=\"https://images.simplywall.st/company/3922204e-9934-411a-90c5-e170feacb161/chart/quote-price\" width=\"746\"/></a><figcaption>EYPT 1-Year Stock Price Chart</figcaption></figure> <p>Some of the lowest estimate analysts were assuming only about 7.9% annual revenue growth and ongoing losses, so compared with those views, you should see Campbell’s appointment and the Phase III dependence as parts of a much more cautious story that might look different once updated forecasts reflect this new hire.</p><p><a class=\"company-report-links\" data-vars-link-type=\"integrated-pitch\" href=\"https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\">Explore 3 other fair value estimates on EyePoint</a> - why the stock might be worth just $36.08!</p><h2>Reach Your Own Conclusion</h2><p>Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.</p><ul><li>A great starting point for your EyePoint research is our analysis highlighting <a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\">2 key rewards and 3 important warning signs</a> that could impact your investment decision.</li><li><a class=\"company-report-links\" data-vars-link-type=\"conclusion\" href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint\" rel=\"noopener noreferrer\" target=\"_blank\">Our free EyePoint research report</a> provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EyePoint's overall financial health at a glance.</li></ul><h2>Want Some Alternatives?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>The latest GPUs need a type of rare earth metal called Neodymium and there are only <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434418/rare-earth-metal-stocks/global\" rel=\"noopener noreferrer\" target=\"_blank\">31 companies in the world exploring or producing it</a>. Find the list for free.</li><li>AI is about to change healthcare. These <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/434426/healthcare-ai/us\" rel=\"noopener noreferrer\" target=\"_blank\">27 stocks are working on everything from early diagnostics to drug discovery</a>. The best part - they are all under $10b in market cap - there's still time to get in early.</li><li>We've uncovered the <a class=\"company-report-links\" data-vars-link-type=\"conclusion-grid\" href=\"https://simplywall.st/discover/investing-ideas/473528/dividend-fortresses/us\" rel=\"noopener noreferrer\" target=\"_blank\">15 dividend fortresses</a> yielding 5%+ that don't just survive market storms, but thrive in them.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.</em></p><div class=\"sc-80c0fb9d-0 hLZAWP\"><h3 class=\"m-0 text-balance text-mega font-medium mb-4 font-serif\">Valuation is complex, but we're here to simplify it.</h3><p>Discover if EyePoint might be undervalued or overvalued with our detailed analysis, featuring <strong>fair value estimates, potential risks, dividends, insider trades, and its financial condition.</strong></p><a class=\"sc-kuACkN kjLJKA !text-[--s-button-primary-color-text] !no-underline\" data-focus=\"dashed\" href=\"/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/valuation\" target=\"_blank\">Access Free Analysis</a></div></div>",
            "pub_date": "2026-03-01 20:37:07",
            "link": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-eypt/eyepoint/news/is-eyepoint-eypt-recasting-its-ophthalmology-playbook-with-a",
            "source": "simplywall",
            "kind": 1,
            "language": "en"
        }
    ]
}